NU-CEFPROZIL 250 MG / 5 ML — DIN 02336359
CEFPROZIL : 250 MG / 5 ML · NU-PHARM INC · POWDER FOR SUSPENSION · wholesale supply in Canada
Health Canada status: CANCELLED (UNRETURNED ANNUAL)
What is NU-CEFPROZIL?
NU-CEFPROZIL 250 MG / 5 ML contains CEFPROZIL : 250 MG / 5 ML. It is listed in the Health Canada Drug Product Database under DIN 02336359, held by NU-PHARM INC, supplied as POWDER FOR SUSPENSION for ORAL administration. Health Canada currently lists it as cancelled (unreturned annual), status dated 28-Mar-2018. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is NU-CEFPROZIL used for?
Pharyngitis/tonsillitis (S. pyogenes), otitis media, acute sinusitis, uncomplicated skin/skin-structure infections, and uncomplicated urinary tract infections (including cystitis).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Cefprozil cost around the world?
Cefprozil is listed on 9 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Bahrain publishes a retail (max); Czechia publishes a max producer price (ex-factory); Greece publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 4 | 25 | USD███.██ |
| Greece | producer price (ex-factory) | 13 | 13 | EUR███.██ |
| Saudi Arabia | public | 7 | 7 | SAR███.██ |
| South Africa | single exit price | 6 | 7 | ZAR███.██ |
| Bahrain | retail (max) | 1 | 3 | BHD███.██ |
| Czechia | max producer price (ex-factory) | 2 | 3 | CZK███.██ |
| Hungary | producer price (ex-factory) | 3 | 3 | HUF███.██ |
| Slovakia | categorised final price | 3 | 3 | EUR███.██ |
| Italy | prezzo al pubblico (classe A) | 2 | 2 | EUR███.██ |
66 pack listings across 41 brand entries and 8 price bases, refreshed 03 Sep 2026. Ranges span every Cefprozil pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Cefprozil in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
10 holders have a Canadian DIN containing Cefprozil, across 34 DINs, of which 7 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| SUN PHARMA CANADA INC | 4 | 4 | SPC-CEFPROZIL, TARO-CEFPROZIL | Sourceable in Canada |
| AURO PHARMA INC | 4 | 3 | AURO-CEFPROZIL | Sourceable in Canada |
| APOTEX INC | 4 | 0 | APO-CEFPROZIL | No marketed DIN |
| AVANSTRA INC | 4 | 0 | AVA-CEFPROZIL | No marketed DIN |
| BRISTOL-MYERS SQUIBB CANADA | 4 | 0 | CEFZIL POWDER FOR ORAL SUSPENSION-125MG/5ML, CEFZIL POWDER FOR ORAL SUSPENSION-250 MG/ 5 ML, CEFZIL TABLETS - 250MG, CEFZIL TABLETS - 500MG | No marketed DIN |
| NU-PHARM INC | 4 | 0 | NU-CEFPROZIL | No marketed DIN |
| SANDOZ CANADA INCORPORATED | 4 | 0 | SANDOZ CEFPROZIL | No marketed DIN |
| RANBAXY PHARMACEUTICALS CANADA INC. | 3 | 0 | CEFPROZIL POWDER FOR ORAL SUSPENSION, CEFPROZIL TABLETS | No marketed DIN |
| MINT PHARMACEUTICALS INC | 2 | 0 | MINT-CEFPROZIL | No marketed DIN |
| PRO DOC LIMITEE | 1 | 0 | CEFPROZIL | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 250 MG / 5 ML |
|---|---|
| Dosage form | POWDER FOR SUSPENSION |
| Route | ORAL |
| Pack configuration (monograph) | Bottles of 50 mL, 75 mL, and 100 mL. |
| Storage | Dry powder: 15°C – 30°C. Reconstituted suspension: Refrigerated (2ºC - 8ºC) for up to 14 days. |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Cefprozil |
|---|---|
| ATC code | J01DC10 |
| AHFS class | 08:12.06.08 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02336359 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2336359 |
| Brand name | NU-CEFPROZIL |
| Generic / active ingredient | CEFPROZIL : 250 MG / 5 ML |
| Market authorization holder | NU-PHARM INC |
| Health Canada schedule | Prescription |
| ATC code | J01DC10 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J01DC |
| Current status | CANCELLED (UNRETURNED ANNUAL) |
| Status date | 28-Mar-2018 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Adults: 250-500 mg q12h or q24h. Children (6 mo-12 yr): 7.5-15 mg/kg q12h or 20 mg/kg q24h. Administered orally with or without food. Max 1 g/day for pediatrics.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Known allergy to the cephalosporin class of antibiotics or to any component of the cefprozil preparations.
Warnings and precautions
Serious hypersensitivity/anaphylaxis risk; cross-sensitivity with penicillin (up to 10%). Pseudomembranous colitis (C. difficile). Risk of overgrowth of nonsusceptible organisms.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
7 of 34 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| AURO-CEFPROZIL | 500 MG | TABLET | AURO PHARMA INC | MARKETED | 02347253 |
| AURO-CEFPROZIL | 250 MG / 5 ML | POWDER FOR SUSPENSION | AURO PHARMA INC | MARKETED | 02347288 |
| AURO-CEFPROZIL | 125 MG / 5 ML | POWDER FOR SUSPENSION | AURO PHARMA INC | MARKETED | 02347261 |
| SPC-CEFPROZIL | 250 MG | TABLET | SUN PHARMA CANADA INC | MARKETED | 02293528 |
| SPC-CEFPROZIL | 500 MG | TABLET | SUN PHARMA CANADA INC | MARKETED | 02293536 |
| TARO-CEFPROZIL | 125 MG / 5 ML | POWDER FOR SUSPENSION | SUN PHARMA CANADA INC | MARKETED | 02329204 |
| TARO-CEFPROZIL | 250 MG / 5 ML | POWDER FOR SUSPENSION | SUN PHARMA CANADA INC | MARKETED | 02293579 |
| APO-CEFPROZIL | 500 MG | TABLET | APOTEX INC | DORMANT | 02293005 |
| APO-CEFPROZIL | 125 MG / 5 ML | POWDER FOR SUSPENSION | APOTEX INC | DORMANT | 02293943 |
| APO-CEFPROZIL | 250 MG | TABLET | APOTEX INC | DORMANT | 02292998 |
2 · Same class — other molecules in ATC J01DC
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Cefuroxime | APO-CEFUROXIME · AURO-CEFUROXIME · CEFTIN · CEFTIN - PWR 250MG/SACHET · +23 more | 44 | 9 | Yes |
| Cefprozil | APO-CEFPROZIL · AURO-CEFPROZIL · AVA-CEFPROZIL · CEFPROZIL · +11 more | 34 | 7 | Yes |
| Cefoxitin | CEFOXITIN FOR INJECTION · CEFOXITIN FOR INJECTION USP · MEFOXIN INJ 1GM/VIAL ADD-VANTAG · MEFOXIN INJ 2GM/VIAL ADD-VANTAG · +3 more | 10 | 2 | Yes |
| Cefaclor | APO-CEFACLOR · CECLOR · CEFACLOR · CEFACLOR CAPSULES · +15 more | 41 | 0 | Not in Canada |
| Cefamandole | MANDOL ADD-VANTAGE INJ 1GM/VIAL · MANDOL INJ 1GM/AMP · MANDOL INJ 2GM/AMP | 3 | 0 | Not in Canada |
| Cefotetan | CEFOTAN INJ 2GM/VIAL · CEFOTAN INJECTION - 1G · CEFOTAN INJECTION - 2 G | 3 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J01D
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J01DB | Cefadroxil · Cefalexin · Cefalotin · Cefazolin | 91 | 41 |
| J01DD | Cefixime · Cefotaxime · Cefpodoxime · Ceftazidime · Ceftizoxime · +1 more | 96 | 25 |
| J01DH | Doripenem · Ertapenem · Imipenem And Cilastatin · Meropenem · Meropenem And Vaborbactam | 51 | 24 |
| J01DE | Cefepime | 10 | 3 |
| J01DF | Aztreonam | 1 | 1 |
| J01DI | Ceftobiprole Medocaril · Ceftolozane And Beta-Lactamase Inhibitor | 2 | 1 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is NU-CEFPROZIL called?
The same molecule, Cefprozil, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| CEFPROZ | Latin | Bahrain |
| CEFZIL | Latin | Czechia |
| CEFZIL O.S. | Latin | Czechia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled (unreturned annual) in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.